Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Palisade Bio, Inc. before investing.

In this article, we go over a few key elements for understanding Palisade Bio, Inc.’s stock price such as:

• Palisade Bio, Inc.’s current stock price and volume
• Why Palisade Bio, Inc.’s stock price changed recently
• Upgrades and downgrades for PALI from analysts
• PALI’s stock price momentum as measured by its relative strength

About Palisade Bio, Inc. (PALI)

Before we jump into Palisade Bio, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Want to learn more about Palisade Bio, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Palisade Bio, Inc..

Palisade Bio, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Palisade Bio, Inc.’s stock price was $1.895.

Palisade Bio, Inc. is down 3.32% from its previous closing price of $1.960.

During the last market session, Palisade Bio, Inc.’s stock traded between $1.855 and $1.950. Currently, there are approximately 209.66 million shares outstanding for Palisade Bio, Inc..

Palisade Bio, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Palisade Bio, Inc. Stock Price History

Palisade Bio, Inc.’s (PALI) price is currently down 9.33% so far this month.

During the month of July, Palisade Bio, Inc.’s stock price has reached a high of $2.220 and a low of $1.840.

Over the last year, Palisade Bio, Inc. has hit prices as high as $2.855 and as low as $0.530. Year to date, Palisade Bio, Inc.’s stock is down 19.36%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Palisade Bio, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Palisade Bio, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Palisade Bio, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Palisade Bio, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Palisade Bio, Inc. (PALI) by visiting AAII Stock Evaluator.

Relative Price Strength of Palisade Bio, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Palisade Bio, Inc. has a weighted four-quarter relative price strength of 14.58%, which translates to a Momentum Score of 88 and is considered to be Very Strong.

Want to learn more about how Palisade Bio, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Palisade Bio, Inc. Stock Price: Bottom Line

As of July 31, 2026, Palisade Bio, Inc.’s stock price is $1.895, which is down 3.32% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Palisade Bio, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.